Informations générales (source: ClinicalTrials.gov)
A Randomized, Subject and Investigator Blinded, Placebo-controlled and Multi-center Platform Study, to Assess Efficacy and Safety of Different Investigational Drugs in Patients With Moderate to Severe Hidradenitis Suppurativa
Interventional
Phase 2
Novartis Pharmaceuticals (Voir sur ClinicalTrials)
février 2019
décembre 2026
29 mars 2025
The main purpose of this study is to assess preliminary efficacy and safety of CFZ533,
LYS006, MAS825 , LOU064 and VAY736 in patients with moderate to severe hidradenitis
suppurativa and to determine if CFZ533, LYS006, MAS825, LOU064 and VAY736 have an
adequate clinical profile for further clinical development.
Etablissements
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Novartis Investigative Site - 06202 - Nice - France | Contact (sur clinicalTrials) | ||||
| Novartis Investigative Site - 13885 - Marseille - France | Contact (sur clinicalTrials) | ||||
| Novartis Investigative Site - 51100 - Reims - France | Contact (sur clinicalTrials) | ||||
| Novartis Investigative Site - 69003 - Lyon - France | Contact (sur clinicalTrials) | ||||
| Novartis Investigative Site - 76031 - Rouen - France | Contact (sur clinicalTrials) | ||||
| Novartis Investigative Site - 92160 - Antony - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
- Patients with moderate to severe HS based on the number of lesions, fistulae and
anatomical areas involved
- Minimal body weight of 50 kg
- Able to communicate well with the investigator and understand and comply with the
requirements of the study, and the ability and willingness to conduct study visits
as per the study schedule
- Patients with moderate to severe HS based on the number of lesions, fistulae and
anatomical areas involved
- Minimal body weight of 50 kg
- Able to communicate well with the investigator and understand and comply with the
requirements of the study, and the ability and willingness to conduct study visits
as per the study schedule
- Use of other investigational drugs at the time of screening or before
- Women physiologically capable of becoming pregnant, unless they are using highly
effective methods of contraception
- Pregnant or lactating women
Other protocol-defined inclusion/exclusion criteria may apply